What has NICE said?

What has NICE said?

Cetuximab (Erbitux) or panitumumab (Vectibix) given with 5‑fluorouracil, folinic acid and oxaliplatin (FOLFOX) or 5‑fluorouracil, folinic acid and irinotecan (FOLFIRI) are recommended. They are possible treatments for RAS wild-type metastatic colorectal cancer in adults that has not been treated before.

What does this mean for me?

If you have RAS wild-type metastatic colorectal cancer that has not been treated before, and your doctor thinks that cetuximab or panitumumab with FOLFOX or FOLFIRI is the right treatment, you should be able to have it on the NHS.

The condition and the treatments

Colorectal cancer, or bowel cancer, affects the colon or rectum. It is metastatic if it has spread to other parts of the body. Colorectal cancer cells can have changes (mutations) in the KRAS genes, which affect how well some treatments work. RAS wild-type colorectal cancer has no KRAS mutations.

Cetuximab and panitimumab slow the growth of RAS wild-type colorectal cancer.

NHS Choices may be a good place to find out more.

These organisations can give you advice and support:

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-2403-5

  • Information Standard